LianBio reports Q4 net loss $21.2M; cash $403.2M; mavacamten Phase 3 ongoing

LianBio

Net loss $21.2M in Q4 2021 vs $12.7M Q4 2020; full-year loss $196.3M vs $139.6M.
Cash, equivalents, marketable securities $403.2M at Dec 31, 2021; runway through 2023.
Phase 3 EXPLORER-CN trial of mavacamten initiated in Chinese oHCM patients; Breakthrough Therapy designation granted.
Infigratinib approved under named patient program for cholangiocarcinoma in Hainan pilot zone.
Three programs (TP-03, NBTXR3, infigratinib) expected to enter Phase 3 in China by end of 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.